The Obama administration has  blocked several big telecoms deals in a bid to protect competition. Photograph: Kevin Lamarque/Reuters

US companies have abandoned $370 billion of large deals since President Barack Obama came into power in 2009, after regulators in his administration b(...)

Photograph: Simon Dawson/Bloomberg

Lower-cost copies of complex biotech drugs, known as biosimilars, could save the United States and Europe’s five top markets as much as €98 billion by(...)

Painting teamwork: AbbVie staff carrying out refurbishing work at St Joseph’s Special School, Sligo AbbVie staff doing refurbishment work at St Joseph’s Special School in Sligo

There are many ways to develop teamwork. Crédit Agricole Credit Insurance (CACI) has 14 nationalities among its 106 employees and the company believe(...)

 Shire has been focusing on acquiring companies with treatments for rare conditions. Photograph: Simon Dawson/Bloomberg

Shire, the pharmaceutical company based in Dublin, is in advanced talks to acquire Baxalta for about $32 billion (€29.5 billion) in cash and stock, ex(...)

AstraZeneca agreed to buy a 55 per cent stake in Acerta Pharma for $4 billion to gain a potential blockbuster cancer medicine.

AstraZeneca agreed to buy a 55 per cent stake in Acerta Pharma for $4 billion to gain a potential blockbuster cancer medicine. The UK’s second-large(...)

Dr Jim Sullivan, vice-president of pharmaceutical discovery at AbbVie: “It is important in basic research to have the talent working well together.” Photograph: Eric Luke/The Irish Times

Ireland’s got talent in scientific research, but we need to keep investing it to attract even more. That’s according to Dr Jim Sullivan of global biop(...)

Gains at Airbus  and Renault  helped European stocks record their best month in more than six years yesterday.  Photographs: Pascal Rossignol.

European stocks recorded their best month in more than six years yesterday, buoyed by gains at carmaker Renault and aircraft maker Airbus while inves(...)

Teva factory sign on its plant in Jerusalem: Teva says its stock-and-cash offer of $82 a share represented a 48 per cent premium to Mylan’s stock price on March 10th, which it said was the last day of trading prior to the widespread speculation. Photograph: Menahem Kahana

Generic drugmaker Teva Pharmaceutical Industries Ltd yesterday proposed buying Mylan for $40 billion, saying it was a better deal than the smaller riv(...)

Shire  “trying to do the right thing” by running the pharmaceuticals company as efficiently as possible, says chief executive Flemming Ornskov

Shire’s chief executive has defended the company’s tax arrangements after being identified as one of the beneficiaries of alleged “industrial scale” (...)

Shire acting chief financial officer Jeff Poulton said the company had obtained advice that the break fee should not be taxable in Ireland. Photograph: The Irish Times

Drug giant Shire is facing a potential tax bill of up to €480 million as Irish Revenue officials examine the fallout from a collapsed takeover of the (...)